These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21522129)

  • 21. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Cho Y; Gorina S; Jeffrey PD; Pavletich NP
    Science; 1994 Jul; 265(5170):346-55. PubMed ID: 8023157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
    Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
    Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.
    Nie Y; Li HH; Bula CM; Liu X
    Mol Cell Biol; 2000 Feb; 20(3):741-8. PubMed ID: 10629029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
    Kamada R; Nomura T; Anderson CW; Sakaguchi K
    J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73.
    Bensaad K; Le Bras M; Unsal K; Strano S; Blandino G; Tominaga O; Rouillard D; Soussi T
    J Biol Chem; 2003 Mar; 278(12):10546-55. PubMed ID: 12519788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA.
    Klein C; Planker E; Diercks T; Kessler H; Künkele KP; Lang K; Hansen S; Schwaiger M
    J Biol Chem; 2001 Dec; 276(52):49020-7. PubMed ID: 11606582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of a p53 core tetramer bound to DNA.
    Malecka KA; Ho WC; Marmorstein R
    Oncogene; 2009 Jan; 28(3):325-33. PubMed ID: 18978813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis of DNA recognition by p53 tetramers.
    Kitayner M; Rozenberg H; Kessler N; Rabinovich D; Shaulov L; Haran TE; Shakked Z
    Mol Cell; 2006 Jun; 22(6):741-753. PubMed ID: 16793544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure of the p53 core domain dimer bound to DNA.
    Ho WC; Fitzgerald MX; Marmorstein R
    J Biol Chem; 2006 Jul; 281(29):20494-502. PubMed ID: 16717092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultraslow oligomerization equilibria of p53 and its implications.
    Natan E; Hirschberg D; Morgner N; Robinson CV; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14327-32. PubMed ID: 19667193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers.
    Rajagopalan S; Jaulent AM; Wells M; Veprintsev DB; Fersht AR
    Nucleic Acids Res; 2008 Oct; 36(18):5983-91. PubMed ID: 18812399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding.
    Sun X; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain.
    Wright JD; Noskov SY; Lim C
    Nucleic Acids Res; 2002 Apr; 30(7):1563-74. PubMed ID: 11917017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.
    Jeffrey PD; Gorina S; Pavletich NP
    Science; 1995 Mar; 267(5203):1498-502. PubMed ID: 7878469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.
    Thukral SK; Blain GC; Chang KK; Fields S
    Mol Cell Biol; 1994 Dec; 14(12):8315-21. PubMed ID: 7969167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Basis for p53 Lys120-Acetylation-Dependent DNA-Binding Mode.
    Vainer R; Cohen S; Shahar A; Zarivach R; Arbely E
    J Mol Biol; 2016 Jul; 428(15):3013-25. PubMed ID: 27338200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA.
    Halazonetis TD; Davis LJ; Kandil AN
    EMBO J; 1993 Mar; 12(3):1021-8. PubMed ID: 8458320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
    Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
    Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.